INTRODUCTION

Anthrax is a highly infectious, zoonotic disease occurring worldwide in domestic as well as wild herbivores. It is caused by gram-positive, rod-shaped, anaerobic and sporulating bacteria *Bacillus anthracis*. Humans and other secondary consumers are infected when they come in contact with contaminated animals or animal products and consume anthrax contaminated meat. The symptoms are manifested in the three forms namely cutaneous, gastrointestinal and inhalational, and result in high mortality.

(i) Cutaneous infection

More than 95% of anthrax cases are cutaneous and occur when the spores come in contact with the injured part of the body, especially skin. People consuming contaminated meat or handling wool, animal hides etc. are more prone to this infection. The incubation period of cutaneous anthrax is about 0.15 to 12 days \(^1,2\) (Fig 1). The primary symptoms are painless lesion at the injection site, nodes swelling, headache, fever and malaise.

(ii) Gastrointestinal infection

This type of anthrax generally occurs after consuming contaminated uncooked meat and the symptoms appear in the form of acute inflammation in the intestinal tract. Gastrointestinal anthrax has 1-7 days of incubation period \(^6\). Preliminary signs are fever, nausea, appetite loss, vomiting of blood, abdominal pain, and bloody diarrhoea \(^7\) (Fig 2 \(^8\)). The fatality rate in this case is about 25-60% \(^1\).

(iii) Inhalational infection

Inhalational anthrax or pulmonary anthrax occurs due to the inspiration of *B. anthracis* spores. The incubation period is reported from 1 to 43 days \(^9\).

Mechanism of Anthrax Pathogenesis

There are two toxic enzymatic effectors proteins involved in the pathogenesis of anthrax which is Lethal Factor (LF) and Edema Factor (EF). The LF is a zinc metalloprotease enzyme and responsible for the lysis of phagocytes leading to a massive release of the secondary messengers. EF is a calcium-activated adenylate cyclase and catalyzes the conversion of ATP to cyclic AMP, which leads to the cellular edema.
and Edema Factor (EF). The LF and EF both bind to a third protein Protective Antigen (PA). PA is cleaved by furin like cell surface proteases and bind to the cell surface receptors molecule, Tumor Endothelial marker 8 (TEM8) and Capillary Morphogenesis Gene 2 (CMG2) and forms a ring-shaped heptamer complex. It enters into the host cell through endocytosis by acidification of the endocytic vacuole. The LF is a zinc metalloprotease which acts as an inhibitor of signal transduction through the mitogen-activated protein kinase (MAPK) cascade by cleaving most MAPK kinases (MAPKKs or MEKs) and preventing the phosphorylation of MAPKs, while EF is a calcium/calmodulin-dependent adenylate cyclase which increases cyclic AMP and leads to edema.

**Treatment**
The only way to treat the deadly anthrax is by vaccination. People living in maximum threat areas have to be vaccinated and prevent the spread of this lethal disease. Described here-with are the available vaccination methods and upcoming vaccination strategies against anthrax.

**Live spore based vaccines**
Live spore vaccine, also known as the Sterne strain vaccine, has proven to be effective in the drastic decline of the anthrax incidences worldwide. These are *B. anthracis* strains based vaccines and do not produce capsule. In Russia, it was known as Zenkowsky strain or STI-1 while in China it was famous as A16R strain. The disadvantage of live spore vaccine is that it causes necrosis at injection site leading to it being discontinued in most countries.

**Protective Antigen (PA) Based Vaccines**
*B. anthracis* strain (V770-NP1-R) in the USA was used as oxygenc, non-capsulated and non-protoelective agent for the treatment of anthrax. Its culture supernatant was used for immunization. Its culture supernatant was adsorbed in aluminum hydroxide and was known as Anthrax vaccine adsorb or AVA and was registered as BioThrax®. An improved version of the same is now available. The advantages of this vaccine are long term immunity by providing multiple booster doses after 12 and 18 months (>5 years). Another PA-based vaccine, alum precipitated culture filtrate of the Sterne strain 34F2 is available in the UK which is registered as Anthrax Vaccine Precipitated (AVP). It generated antibodies against PA, which have anthrax toxins neutralization activity and provide immunity against anthrax. Though AVA and AVP are advantageous over live spore vaccines, their widespread use is hindered by the fact that they take long time to generate protective immunity that effects post-exposure anthrax prophylaxis. Besides, it is suitable for a limited animal model for potency testing.

Consequently, the call of the hour was to bring about an improvement in the existing vaccination strategies along with additional immunogens, expansion of novel adjuvants, novel delivery methods and agents for a safer and more convenient effective new generation anthrax vaccine. The new generation anthrax vaccines which are at different stages of development are described below.

**Live bacterial vaccines**
Many live bacterial vaccines are under process like sporegenic *Bacillus subtilis* transformants, Attenuated *B. anthracis* strains expressing rPA or mutant PA or LF, psoralen-killed but metabolically active (KBMA) *B. anthracis* Sterne vaccines, aromatic amino acid-deficient *B. anthracis* Sterne mutants and many other live attenuated strains of bacteria modified through recombinant DNA technology to express PA in vivo (e.g., *Salmonella, Lactobacillus*) and evaluated for their potency as oral vaccine. The oral vaccines based on *Salmonella*, *Lactobacillus* have potential advantages in providing protection in animal models against spore challenge. However, culturing and storage requirements of this vaccine offer a serious limitation to its usage.

**Recombinant PA based vaccines**
PA has been well established as the key component of anthrax vaccine. Protective antigen (PA) is the non toxic component of the *B. anthracis*, due to this non toxic property it could be an ideal candidate for anthrax vaccine. The single-dose of PA-based anthrax vaccine could elicit an effective immunity, safe and efficacious against *B. anthracis*. New generation vaccines propose the development of recombinant PA vaccines for anthrax treatment. The expression system which is based on *Escherichia coli* for preparation of recombinant PA (rPA) served as the receptor for enzymatic moieties of anthrax toxins (ATs) and elicited toxin neutralizing antibodies (tested in white rabbits and rhesus macaques against an aerosol containing *Bacillus anthracis* spores (IVRI strain, tox+ cap+). In other hosts, the similar expression of RPA gene has been also evaluated like the attenuated strain of *B. anthracis, Saccharomyces cerevisiae, Baculovirus, Vaccinia virus* and tested for providing protection against *B. anthracis*. Further, many rPA proteins purified from *B. anthracis* and *E. coli* combined with aluminium-based adjuvants are under clinical trial as next-generation anthrax vaccine. Besides these, numerous antigen-based delivery methods like microspheres, nanoemulsions, nanoparticles and liposomes and others with variable success have been applied to improve the immunogenicity. The PA-based liposomal formulation has been reported to induce high titers of Lethal Toxin (LeTx), neutralizing antibodies and confer complete protection against challenge.
However, this system of vaccination exhibits variability in the extent of the immune response in different experimental model organisms. Overall the advancement in PA-based vaccines (i.e., recombinant, purified, modified), failed in providing complete protection as like RVA and other conventional vaccines.

**Capsule vaccines**
The capsule vaccines are polysaccharides which provide protection against bacterium phagocytosis by generating humoral immune response. *B. anthracis* poly-gamma-d-glutamic acid (γDPGA) capsule covalently conjugated with membrane protein of *Neisseria meningitides* serotype B and was reported to protect mice against parenteral anthrax challenge. The γDPGA capsule based vaccine significantly protects monkeys, but not rabbits, against aerosolized *B. anthracis* spore challenge. However, it has been observed by ELISA and a macrophage opsono-adherence assay that the γDPGA capsule-based vaccine induced robust anti-capsule antibody responses in both species. In another study, the complete protection against cutaneous anthrax were observed when γDPGA peptidoglycan preparation (GluPG) is conjugated with PA. Developed sortase-conjugation method (linking the γDPGA capsule to the receptor binding domain (D4) of PA) for improving the earlier used random chemical cross-linking. The construct elicited robust antibody response against both the antigens and conferred complete protection against wild-type or *pagA* mutant *B. anthracis* Ames strain in guinea pigs developed a dual vaccine by conjugating the γDPGA capsule with PA, which elicited antibodies against both the bacilli and toxin component. The native PA was replaced with dominantly negative inhibitory PA mutant. This resulted in improved immunogenic response. In another study, intranasal immunization of mice with PA and PGA-BSA protein conjugate exhibited an immune response against both PA and PGA. The anti-PA antibodies have the capability to neutralize the LeTx while anti-PGA antibodies can kill PGA-producing bacteria by complement activation. It is also anticipated that the addition of the capsule can further improve PA-based vaccines. Experiment

**Epitope vaccines**
The epitope is the part of an antigen molecule to which an antibody is attached also known as the antigenic determinant. Multiple antigenic peptides (MAPs) displaying aa 304–319 or 305–319 from domain 2 of PA (loop domain) have been shown to elicit antibodies specific to a linear determinant in PA and mediated high-titer neutralization of LeTx *in vitro*. Besides, immunogenicity and protective efficacy of MAP in conjunction with a heterologous T-cell epitope from *Plasmodium falciparum* was investigated in rabbits. It was reported to elicit toxin neutralizing antibodies and provide protection from aerosolized spores of *B. anthracis* Ames strain. In another development it was demonstrated that strong immunogenicity of ID-II epitope (aa 626–676 of PA) showing protection with whole PA. Many AT neutralization-associated humoral epitopes have been identified using solid-phase epitope mapping and confirmatory assays. The studies have established the feasibility of the use of epitopes for anthrax prophylaxis making them a prospective candidate for effective vaccination

**Subunit vaccines**
Evaluation of PA domain for subunit vaccines is also being envisioned as the next generation vaccines after a better understanding of molecular pathogenesis, immune mechanisms and structure of PA has been developed over the past several years. In a study, it was found that the conjugation of LF and EF in engineered strains expressing PA and EF/LF which resulted in keen antibody response and offered more protection as compared to the strains expressing only PA. Further developments in this direction resulted in the preparation of antibodies which are directed against anthrax PA domain 4 (PA-D4) which protects mice from *B. anthracis* infection. It was concluded that addition of other *B. anthracis* proteins or protein domains can improve the efficacy of PA-D4 based vaccine. In another study, it has been found that fusion products of PA, LF and EF on bacteriophage T4 capsid demonstrated a strong antigen-specific response and LeTx neutralizing antibodies as compared to the phage displaying PA alone. Yet another study states that immunization with a hybrid molecule composed of the key domains of PA and LF elicited PA and LF specific antibodies with LeTx neutralizing antibodies and protected rabbits against *B. anthracis*. This led to the conclusion that the fusion conferred robust protection against anthrax infection as compared to PA alone.

**Plant vaccines (Oral Vaccine)**
The vaccines which are based on the plant are environmental and eco-friendly, easy to use, economical, devoid of any animal or pathogens and least challenging for manufacture/process development. More importantly, they provide both humoral and cell-mediated immune response along with providing long-lasting immunity. Several researchers have already reported the expression of PA in transgenic chloroplast. The expressed PA in transgenic chloroplast has antibodies neutralization ability which reduces the cost of protein expression. In a study it was found that more than 360 million doses of PA-based anthrax vaccine yielded in one-acre transgenic tobacco plantation. Expression of rPA in tomato was shown to be stable at higher temperature with no requirements of cold storage, transportation issues and PA purification. The transgenic chloroplast containing expressed PA-D4 has 5.3% of total soluble protein, which has the ability to protect the mice against *B. anthracis* spores.
after oral immunization. In another study, a subunit vaccine comprising PA-D4 and domain I of LF as fusions to lichenase (LicKM – a thermostable enzyme from Clostridium thermocellum), expressed in Nicotiana benthamiana – was shown to generate LeTx neutralizing antibodies. Consequently, edible vaccines can be looked up as an alternate source of anthrax vaccine with additional benefits of being economical and suitable for mass immunization.

DNA vaccines
DNA vaccines are expected to be advantageous because it is easy for construction, and offers the scope of combining different antigens, lowering the cost of production by eliminating the need for protein expression and antigen purification. A cationic lipid-based bivalent DNA vaccine encoding genetically detoxified PA and LF proteins was tested against B. anthracis spores. The mice models have shown promise in nonhuman primates and passed the clinical trial evaluating immunogenicity and safety parameters. The evidence of immunogenicity and type of immune response generated by DNA vaccines can be further modified and enhanced by targeting the antigen to different cellular location.

Virus & virus-like particle vaccines
Virus-like particles (VLPs) are multi-protein structures which mimic the organization and conformation of native viruses but lack the viral genome. There are many live viral vaccines produced which have best protection capacity against anthrax spores like adenovirus-based, Venezuelan equine encephalitis virus-vectored vaccines, Parvovirus B19 has been used for the expression of VLP conjugated PA-D4 which have robust neutralizing anti-PA antibody. The Flock House virus have high affinity PA-binding domain at Anthrax toxin cell receptor which shows multiple copied of affinity. A group of researcher have identified that the chimeric VLP inhibit the toxicity of lethal toxin while binding with PA. Therefore, the non-infectious VLPs are considered as an effective method for neutralizing the anthrax toxins at cell surface receptors. However, only a little work has been done in this direction calling for more research inputs.

Nanotechnology based vaccines
Nanotechnology marks a new era in the field of medicines and having a wide range of applications in treatments, drug delivery, tissue engineering and diagnostics. Recently the nano-particle delivery based micro-encapsulated in poly (lactide co-glycolide) (PLGA) forms of PA and Domain 4 were developed but their efficacy remains to be proven. For this reason, a new suitable alternative of next-generation anthrax vaccine is necessary. Nano-particle based approach using silver or gold nanoparticles as nano-conjugates of PA and PA-D4 seems to be a new possibility with numerous unexplored potentials.

Table 1 summarizes the different types of vaccines used for anthrax treatment.

CONCLUSION
Anthrax treatment has been a challenge to the clinicians across the globe resulting in constant efforts towards the development of efficient vaccination for the disease. While conventional vaccines are still being used, the requirement of multiple booster doses has accounted for high cost and shortage of conventional vaccines for all. It has, therefore, become imperative not only to identify alternative immunogens for immunization against anthrax toxins but also look out for alternative vaccination strategies. Several types of research have shown potential candidature in next-generation vaccines which may have single shot requirements, are cost-effective, eco-friendly, easy to handle and efficacious. The need of the hour is to put in more concerted efforts towards development, testing and use of these new generation vaccines.

ACKNOWLEDGEMENT
The authors would like to acknowledge Graphic Era University, for providing all necessary support in completing the study. The authors also express their sincere thanks to the authors/editors/publishers of all those articles that helped us in collecting and compiling essential information for the preparation of this manuscript.

Conflict of Interest: The authors declare that they have no conflicts of interest for this study.

Source of Funding: Nil

REFERENCES
1. Bacterial infections of humans. Brachman Philip S eds. Anthrax In: Evans AS New York: Plenum Medical Book Company; 1998: 95-111.
2. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine. 1991; (9):533–539.
3. Bacterial infections of humans. Brachman Philip S eds. Anthrax In: Evans AS New York: Plenum Medical Book Company; 1998: 95-111.
4. Dixon T, Meselson M, Guillemain, Hanna P. Anthrax Medical progress, Review art. New Eng J.Med. 1999;341:815-826.
5. Ashford DA, Perkins BA, Rotz L. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report. 2000; 49(RR-15):1–22.
6. https://www.cdc.gov/anthrax/basics/types/index.html.(Access on 260820).
7. Tekin A, Bulut N, Unal T. Acute abdomen due to anthrax. Br J Surg. 1997, 84:813.
8. Brachman PS, Friedlander AM. In: Anthrax Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds). Saunders WB, Philadelphia, PA, USA. 1999:629–637.

9. Meselson M, Guineillem J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994 Nov 18;266(5188):1202–8.

10. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JAT. Identification of the cellular receptor for anthrax toxin. Nature. 2001 Nov 4;414(6860):225–299.

11. Scobie HM, Rainey GJA, Bradley KA, Young JAT. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A. 2003;100(9):5170–4.

12. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7045–8.

13. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci. USA. 1982;79:3162–3166.

14. https://shodhganga.inflibnet.ac.in/handle/10603/21020.(Access on 021219)

15. WHO. www.who.int/csr/resources/publications/anthrax_web.pdf. (Access on 070820).

16. Duesbery NS, Vande Woude GF. Anthrax toxins. Cell Mol Life Sci. 1999 Sep;55(12):1599–609.

17. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine. 1994 Jan 1;12(8):727–30.

18. Bacillus anthracis (Anthrax) Resource Guide. Anthrax Antibodies. http://pathema.jcvi.org/cgi-bin/ Bacillus/shared/HtmlPage. cgi?page=anthrax_antibodies. (Access on 070820).

19. Auerbach S, Wright GG. Studies on Immunity in Anthrax: VI. Immunizing Activity of Protective Antigen Against Various Strains of Bacillus Anthracis. The Journal of Immunology. 1955 Aug 1;75(2):129–33.

20. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine. 1998 Jul 1;16(11–12):1141–8.

21. FAA. BioThrax® (Anthrax Vaccine Adsorbed). www.fda.gov/downloads/BiologicsBlood-Vaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/UCM074923.pdf. (Access on 070820).

22. Brachman PS, Friedlander AM. In: Anthrax Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds). Saunders WB, Philadelphia, PA, USA. 1999:629–637.

23. Ivins BE, Pitt MLM, Fellows PF, Farchaus JW, Benner GE, Waag DM, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998 Jul;16(11–12):1141–8.

24. Duesbery NS, Vande Woude GF. Anthrax toxins. Cell Mol Life Sci. 1999 Sep;55(12):1599–609.

25. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham BA, Brachman PS, Friedlander AM. In: Anthrax Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds). Saunders WB, Philadelphia, PA, USA. 1999;629–637.

26. Ngundi MM, Meade BD, Little SF, Quinn CP, Corbett CR, Brady RA, et al. Analysis of Defined Combinatorial Antibodies in Anthrax Toxin Neutralization Assays and Their Synergistic Action. Clin Vaccine Immunol. 2012 May 1;19(5):731–9.

27. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine. 2001 Apr 30;19(23–24):3241–7.

28. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham BA. Field Evaluation of a Human Anthrax Vaccine. Am J Public Health Nations Health. 1962 Apr;52(4):632–45.

29. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 2001 Sep 14;19(32):4768–73.

30. Fellows PF, Linscott MK, Ivins BE et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine. 2001;19(19):3241–3247.

31. Chawla A, Midha S, Bhatnagar R. Studies on Immunity in Anthrax: VI. Immunizing Activity of Protective Antigen Against Various Strains of Bacillus Anthracis. The Journal of Immunology. 1955 Aug 1;75(2):129–33.

32. WHO. Anthrax vaccines: past, present and future. Vaccine. 1998 Jul 1;16(11–12):1141–8.

33. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham BA. Field Evaluation of a Human Anthrax Vaccine. Am J Public Health Nations Health. 1962 Apr;52(4):632–45.

34. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 2001 Sep 14;19(32):4768–73.
44. Hepler RW, Kelly R, McNeely TB, Fan H, Losada MC, George HA, et al. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine. 2006 Mar 6;24(10):1501–14.

45. Worsham PL, Sowers MR. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can J Microbiol. 1999 Jan;45(1):1–8.

46. Campbell JD, Clement KHL, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin. 2007 Oct;3(5):205–11.

47. Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, et al. Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice. Infect Immun. 2002 Apr;70(4):2022–8.

48. Bielinska AU, Janczak KW, Landers JJ et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immunol. 2007;75(8):4020–4029.

49. Knockenhauer KE, Sawicka KM, Roemer EJ, Simon SR. Protective antigen composite nanofoams as a transdermal anthrax vaccine. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:1040–3.

50. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm. 2007 Mar 1;331(2):228–32.

51. Petersen LK, Phanse Y, Ramer-Tait AE, Wannemuehler MJ, Narasimhan B. Amphiphilic Polyanhydride Nanoparticles Stabilize Bacillus anthracis Protective Antigen. Mol Pharm. 2012 Apr 2;9(4):874–82.

52. Peachman KK, Li Q, Matyas GR, Shivchandra SB, Lovchik J, Lyons RC, et al. Anthrax Vaccine Antigen–Adjuvant Formulations Completely Protect New Zealand White Rabbits against Challenge with Bacillus anthracis Ames Strain Spores. Clin Vaccine Immunol. 2012 Jan;19(1):11–6.

53. Erzell null, Welkos null. The capsule of bacillus anthracis, a review. J Appl Microbiol. 1999 Aug;87(2):250.

54. Joyce J, Cook J, Chabot DJ et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 2006;281(8):4831–4843.

55. Chabot DJ, Joyce J, Caulfield M, Cook J, Hepler R, Wang S, et al. Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys. Vaccine. 2012 Jan 20;30(5):846–52.

56. Candela T, Dumetz F, Tosi-Couture E, Mock M, Goossens PL, Fouet A. Cell-wall preparation containing poly-r-D-glutamates covalently linked to peptidoglycan, a straightforward extractable method, protects mice against experimental anthrax infection. Vaccine. 2012 Dec 17;30(51):171–5.

57. Garufi G, Wang YT, Oh SY, Maier H, Missiakas DM, Schneewind O. Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis. Vaccine. 2012;30(23):3435–3444.

58. AulingBA, Roehrl MH, Mekalanos JJ, Collier RJ, Wang JY. Combining Anthrax Vaccine and Therapy: a Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for Vaccines. Infect Immun. 2005 Jun;73(6):3408–14.

59. Sloat BR, Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine. 2006;24(40–41):6405–6413.

60. Oscherwitz J, Yu F, Jacobs JL, Liu TH, Johnson PR, Cease KB. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect. Immunol. 2009;77(8):3380–3388.

61. Oscherwitz J, Yu F, Cease KB. A Synthetic Peptide Vaccine Directed against the 2β2–2β3 Loop of Domain 2 of Protective Antigens Protects Rabbits from Inhalation Anthrax. JI. 2010 Sep 15;185(6):3661–8.

62. Kaur M, Chug H, Singh H, Chandra S, Mishra M, Sharma M, et al. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol Immunol. 2009 Jun;46(10):2107–15.

63. Crowe SR, Ash LL, Engler RJ et al. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J. Infect. Dis. 2010;202(2):251–260.

64. Bramwell VW, Eyles JE, Oya Alpar H. Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev. 2005 Jun 17;57(9):1247–65.

65. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun. 1995 Apr;63(4):1369–72.

66. Flick-Smith HC, Eyles JE, Hebdon R et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immunol. 2002;70(4):2022–2028.

67. Shivchandra SB, Li Q, Peachman KK et al. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine. 2007;25(7):1225–1235.

68. Li Q, Peachman KK, Sower L, Leppa SH, Shivchandra SB, Matyas GR, et al. Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits. Open Vaccine J. 2009;2:92–9.

69. Quinn CP, Sabourin CL, Niemuth NA et al. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol. 2012;19(11):1730–1745.

70. Ascough S, Ingram RJ, Altmann DM. Anthrax lethal toxin and the induction of CD4 T cell immunity. Toxins (Basel). 2012;4(10):878–99.

71. Aziz MA, Singh S, Anand Kumar P, Bhatnagar R. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Biophys Res Commun. 2002 Dec 6;299(3):345–51.

72. Koya V, Moayeri M, Leppha SH, Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect. Immunol. 2005;73(12):8266–8274.

73. Koya V, Moayeri M, Leppha SH, Daniell H. Plant-Based Vaccine: Mice Immunized with Chloroplast-Derived Anthrax Protective Antigen Survive Anthrax Lethal Toxin Challenge. Infect Immun. 2005 Dec;73(12):8266–74.

74. Aziz MA, Sikriwal D, Singh S, Jarugula S, Kumar PA, Bhatnagar R. Transformation of an edible crop with the pagA gene of Bacillus anthracis. FASEB J. 2005 Sep;19(11):1501–3.

75. Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, Chandra S, et al. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax. Vaccine. 2011 Jun 15;29(27):4521–33.

76. Chichester JA, Musiychuk K, de la Rosa P et al. Immunogenicity and the induction of CD4 T cell immunity. Toxins (Basel). 2012;4(10):878–99.

77. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, et al. A cationic lipid-formulated plasmid DNA vaccine...
Kumar et al.: Pandemic and vaccines – the case of deadly anthrax infection, vaccine development and evolution

confers sustained antibody-mediated protection against aerosolized anthrax spores. PNAS. 2004 Sep 14;101(37):13601–6.
78. Keitel WA, Treanor JJ, El Sahly HM et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum. Vaccin. 2009;5(8):536–544.
79. Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010 Oct;9(10):1149–76.
80. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther. 2007 Jan;15(1):203–10.
81. Lee JS, Hadjipanayis AG, Welkos SL. Venezuelan equine encephalitis virus vectored vaccines protect mice against anthrax spore challenge. Infect. Immunol. 2003;71(3):1491–1496.
82. Ogasawara Y, Amexis G, Yamaguchi H, Kajigaya S, Leppla SH, Young NS. Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen. In Vivo. 2006;20(3):319–324.
83. Manayani DJ, Thomas D, Dryden KA et al. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS pathog. 2007;3(10):1422–1431.
84. Marbanjiang E, Donboklang. Nanotechnology- a new era in medicine and diagnostics. IJCRR. 2014 Dec; 6 (24): 7-10
85. Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS ONE. 2013;8(4):e61885.

Table 1: Advantages and Limitations of available Anthrax vaccines

| S.N. | Vaccine | Advantages | Limitations |
|------|---------|------------|-------------|
| 1    | Livespore based vaccines | No capsule formation. | Necrosis at injection site. |
| 2    | Protective Antigen (PA) Based Vaccines | Long term immunity. | Requires multiple booster doses. |
| 3    | Live bacterial vaccines | Protection in animal models against spore challenge. | Requirement of specific culturing and storage conditions |
| 4    | Recombinant PA based vaccines | Provides high titer of Lethal Toxin (LeTx), neutralizing antibodies. | Not better than conventional vaccines |
| 5    | Capsule vaccines | Significant protection to monkeys by yDPGA capsule based vaccine. | Failure in protecting rabbits against infection |
| 6    | Epitope vaccines | Protection from aerosolized B. anthracis spores, toxin neutralization. | Restricted to Ames strain, not yet proven against other B. anthracis strains |
| 7    | Subunit vaccines | Strong antigenic response with fusion products of PA, LF and EF | No antigenic response against PA alone. |
| 8    | Plant vaccines (Oral Vaccine) | Eco-friendly, easy to use, economical, devoid of pathogens, ease of manufacture /process development | Varied response, stability issues. |
| 9    | DNA vaccines | Ease of construction, scope of antigen combinations, combining different antigens, no need of protein expression and antigen purification, cost effective | Failure in antigen targeting to different cellular locations. |
| 10   | Virus & virus-like particle vaccines | Effective for neutralizing the anthrax toxins at cell surface receptors | Limited work done, needs further validation. |
| 11   | Nano technology based vaccines | Environmental friendly, cost effective. | Efficacy yet to be validated |
Kumar et al.: Pandemic and vaccines – the case of deadly anthrax infection, vaccine development and evolution

**Figure 1:** Cutaneous Infection.

**Figure 2:** Gastrointestinal Infection.

**Figure 3:** Mechanism of Anthrax infection.